Cowen & Co

Analysts at Cowen & Co upgrade AnnTaylor Stores Corp (NYSE: ANN) from "underperform" to "neutral." ANN's shares lost 1.48% to close at $20.58 yesterday. More Analyst Ratings here

Bloomberg has quoted unidentified sources as saying that Genzyme (NASDAQ: GENZ) has refused the takeover offer from Sanofi-Aventis (NYSE: SNY). GENZ is, maybe, holding out for a better offer. Analyst Phil Nadeau of Cowen & Co said that it is just a matter of time, “given that Genzyme has...

Analysts at Cowen & Co maintain their "neutral" rating on Isis Pharmaceuticals (NASDAQ: ISIS). Isis and GlaxoSmithKline (NYSE: GSK) have collaborated as a result of which ISIS will develop a maximum of six antisense candidates for rare and serious diseases. Cowen & Co does not consider the...

Analysts at Cowen & Co downgrade Synaptics (NASDAQ: SYNA) from "outperform" to "neutral," while lowering their estimates for the company. According to Cowen & Co, the downgrade in the rating is based on slower growth in the handset segment. The analysts expect Synaptics to maintain its...

Analysts at Cowen & Co maintain their "outperform" rating on United Therapeutics (NASDAQ: UTHR). United Therapeutics reported Q4 revenues ahead of expectations, driven by strong Tyvaso revenues. Earnings missed expectations due to higher SG&A and R&D expenses, the analysts say. “We...

Analysts at Cowen & Co maintain their "outperform" rating on Gilead Sciences Inc (NASDAQ: GILD). Numerical data from the Phase II proof-of-concept studies of Gilead Sciences’ Quad Combo pill and GS9350, GILD’s proprietary PK booster, were solid. The results “provide us with increased confidence...

Analysts at Cowen & Co maintain their "neutral" rating on Alliant Techsystems (NYSE: ATK). Cowen & Co believes that the consensus revenues and EPS for Alliant Techsystems will be lowered for 2H10, as NASA’s F11 budget request seeks to terminate the “Constellation” program and retire the...

Analysts at Cowen & Co maintain their "outperform" rating on Forest Labs (NYSE: FRX). According to Cowen & Co, Forest Labs, during its Analyst Day meeting on Thursday, is expected to provide an update on its late-stage pipeline. The analysts expect the meeting to be a catalyst for FRX’s...

Analysts at Cowen & Co maintain their "outperform" rating on Global Payments (NYSE: GPN). According to Cowen & Co, Global Payments has restructured its money transfer segment successfully and is witnessing stabilizing margins. GPN continues to gain market share in the UK, the analysts say....

Analysts at Cowen & Co maintain their "outperform" rating on Merck & Co Inc (NYSE: MRK), while raising their estimates for the company. According to Cowen & Co, the upward revision in the estimates is to reflect Merck’s SGP merger and the associated cost savings. The analysts expect MRK...

Analysts at Cowen & Co maintained their "outperform" rating on MasterCard Inc (NYSE: MA). According to Cowen & Co, MasterCard is highly leveraged to an economic recovery and a consumer spending recovery. MA is also poised to benefit from an improvement in credit trends in North America,...

Analysts at Cowen & Co maintained their "underperform" rating on News Corporation (NYSE: NWS). According to Cowen & Co, the recent release of the film Avatar is unlikely to drive meaningful upside to the consensus estimates. Although the film has witnessed a solid opening, the results were...

Analysts at Cowen & Co maintain their "outperform" rating on L-3 Communications (NYSE: LLL)(FREE stock trend analysis). According to Cowen & Co, L-3 Communications’ 2010 EPS is likely to be ahead of the guidance due to improved business prospects and increased M&A potential. Moreover,...

Analysts at Cowen & Co reiterate their “neutral” rating on Ascent Solar Technologies (NASDAQ: ASTI), while raising their estimates for the company. According to Cowen & Co, ASTI’s current capacity plan has caused a delay in the timing to full volume in Fab2 and Fab3. However, the adverse...

Analysts at Cowen & Co reiterate their “outperform” rating on Genzyme (NASDAQ: GENZ), while reducing their estimates for the company. According to Cowen & Co, GENZ is no longer expected to launch Lumizyme in the US in 2010. Genzyme is likely to cater to 30% of Fabrazyme demand in 1Q10 and...